Drug Profile
GBV 006
Alternative Names: GBV-006Latest Information Update: 28 Apr 2022
Price :
$50
*
At a glance
- Originator Stanford University School of Medicine
- Developer Globavir Biosciences
- Class Antivirals
- Mechanism of Action Virus internalisation inhibitors; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II COVID 2019 infections
- Preclinical Hantavirus infections; Lassa fever; Marburg virus disease
- No development reported Dengue
- Discontinued Ebola virus infections; Respiratory syncytial virus infections
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for phase-I development in Dengue in USA
- 03 Feb 2022 Discontinued - Phase-II for Ebola virus infections in USA (unspecified route) (Globavir Biosciences pipeline, February 2022)
- 03 Feb 2022 Discontinued - Preclinical for Respiratory syncytial virus infections in USA (unspecified route) (Globavir Biosciences pipeline, February 2022)